专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2009137078A1 COMPOSITIONS OF PEPTIDES AND PROCESSES OF PREPARATION THEREOF 审中-公开
标题翻译：肽的组合物及其制备方法
公开(公告)号：WO2009137078A1
公开(公告)日：2009-11-12
申请号：PCT/US2009/002842
申请日：2009-05-07
申请人： MERRION RESEARCH III LIMITED , LEONARD, Thomas, W.
发明人： LEONARD, Thomas, W.
IPC分类号： A61K38/09 , A61K47/06
CPC分类号： A61K38/09 , A61K9/2846 , A61K9/4891 , A61K47/12 , A61K47/14 , C07K7/06
摘要： The present invention provides composition of comprising a therapeutically effective amount of at least one peptide, polypeptide, analog or derivative thereof and a sufficient amount of at least one stabilizing agent to improve the stability of the peptide, polypeptide, an analog or derivative thereof, wherein at least one stabilizing agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent. The method for preparation of a composition of a peptide, polypeptide, protein, an analog and/or derivative thereof is also provided. The process comprises mixing the peptide, polypeptide, protein, an analog or derivative thereof with a sufficient amount of at least one stabilizing agents to improve the stability of the peptide, polypeptide, protein, an analog or derivative thereof, and the agent is a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.
摘要翻译：本发明提供包含治疗有效量的至少一种肽，多肽，类似物或衍生物和足够量的至少一种稳定剂以提高肽，多肽，其类似物或衍生物的稳定性的组合物，其中至少一种稳定剂是中链脂肪酸盐，酯，醚或中链脂肪酸的衍生物，并且具有约4至约20个碳原子的碳链长度或者是表面活性剂。还提供了制备肽，多肽，蛋白质，其类似物和/或衍生物的组合物的方法。该方法包括将肽，多肽，蛋白质，其类似物或衍生物与足够量的至少一种稳定剂混合以改善肽，多肽，蛋白质，其类似物或衍生物的稳定性，并且该药剂是培养基链脂肪酸盐，酯，醚或中链脂肪酸的衍生物，并且具有约4至约20个碳原子的碳链长度或者是表面活性剂。

12. 发明申请

WO2010099255A1 COMPOSITION AND DRUG DELIVERY OF BISPHOSPHONATES 审中-公开
标题翻译：组合物和药物递送双膦酸盐
公开(公告)号：WO2010099255A1
公开(公告)日：2010-09-02
申请号：PCT/US2010/025305
申请日：2010-02-25
申请人： MERRION RESEARCH III LIMITED , LEONARD, Thomas W.
发明人： LEONARD, Thomas W.
IPC分类号： A01N57/00 , A61K31/675
CPC分类号： A61K31/675 , A61K9/2013 , A61K9/2846
摘要： The present invention provides methods of treating or preventing a medical condition that is responsive to a bisphosphonate compound in a subject. The methods comprise administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the bisphosphonate no less frequently than a bi-weekly dosage schedule. In some embodiment, the bisphosphonate compound is zoledronic acid.
摘要翻译：本发明提供了治疗或预防对受试者中双膦酸化合物有反应的医学病症的方法。所述方法包括给予受试者包含治疗有效量的双膦酸盐的药物组合物，不低于每两周一次的剂量方案。在一些实施方案中，双膦酸化合物是唑来膦酸。

13. 发明申请

WO2012082209A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION 审中-公开
标题翻译：选择性因子XA抑制剂用于口服管理的药物组合物
公开(公告)号：WO2012082209A1
公开(公告)日：2012-06-21
申请号：PCT/US2011/052963
申请日：2011-09-23
申请人： MERRION RESEARCH III LIMITED , LEONARD, Thomas W. , COUGHLAN, David C. , CULLEN, Alan
发明人： LEONARD, Thomas W. , COUGHLAN, David C. , CULLEN, Alan
IPC分类号： A61K9/00
CPC分类号： A61K31/702 , A61K9/2833 , A61K47/12
摘要： The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.
摘要翻译：本发明提供用于口服给药的药物组合物，其包含治疗有效量的选择性因子Xa抑制剂或其药学上可接受的盐和增强剂，其中所述增强剂是中链脂肪酸或其盐，酯，醚或衍生物中链脂肪酸，碳链长为4〜20个碳原子。本发明还提供一种在口服给药后在受试者中获得选择性因子Xa抑制剂的可重复生物利用度的方法，包括口服给药如上所述的药物组合物。

14. 发明申请

WO2011094531A1 SOLID PHARMACEUTICAL COMPOSITION WITH ENHANCERS AND METHODS OF PREPARING THEREOF 审中-公开
标题翻译：具有增强剂的固体药物组合物及其制备方法
公开(公告)号：WO2011094531A1
公开(公告)日：2011-08-04
申请号：PCT/US2011/022908
申请日：2011-01-28
申请人： MERRION RESEARCH III LIMITED , COUGHLAN, David C. , LEONARD, Thomas W. , ADAMCZYK, Bozena , MADIGAN, Kieran , O'TOOLE, Edel , CULLEN, Alan , O'HARA, Jason
发明人： COUGHLAN, David C. , LEONARD, Thomas W. , ADAMCZYK, Bozena , MADIGAN, Kieran , O'TOOLE, Edel , CULLEN, Alan , O'HARA, Jason
IPC分类号： A61K9/20
CPC分类号： A61K31/663 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2095 , A61K31/727 , A61K47/12
摘要： The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.
摘要翻译：本发明提供了当给予胃肠道时有效地向受试者提供治疗有效的治疗活性成分的血液水平的药物组合物。一方面，药物组合物包含治疗有效量的治疗活性成分; 至少一种水溶性增强剂，例如中链脂肪酸或中链脂肪酸的盐，酯，醚或衍生物，并且具有约4-约20个碳原子的碳链长度; 和糖。

15. 发明申请

US20150238561A1 Compositions of GnRH related compounds and processes of preparation 审中-公开
公开(公告)号：US20150238561A1
公开(公告)日：2015-08-27
申请号：US14636756
申请日：2015-03-03
申请人： Merrion Research III Limited
发明人： Amanda Lee , Bozena Adamczyk , David C. Coughlan , Edel O'Toole , Thomas W. Leonard
IPC分类号： A61K38/09 , A61K47/12 , C07K7/06
CPC分类号： A61K38/09 , A61K9/2846 , A61K9/4891 , A61K47/12 , A61K47/14 , C07K7/06
摘要： The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.

16. 发明授权

US08828431B2 Solid oral dosage form containing an enhancer 有权
标题翻译：含有增强剂的固体口服剂型
公开(公告)号：US08828431B2
公开(公告)日：2014-09-09
申请号：US13690082
申请日：2012-11-30
申请人： Merrion Research III Limited
发明人： Kenneth Iain Cumming , Zebunnissa Ramtoola
IPC分类号： A61K9/20 , A01N25/34 , A61K9/26 , A61K9/00 , A61K47/12 , A61K9/16 , A61K9/28
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译：本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有碳链长度为6至20个碳原子。优选地，固体口服剂型是控释剂型，例如延迟释放剂型。

17. 发明申请

WO2009137080A1 COMPOSITIONS OF GNRH RELATED COMPOUNDS AND PROCESSES OF PREPARATION 审中-公开
标题翻译： GNRH相关化合物的组合物和制备方法
公开(公告)号：WO2009137080A1
公开(公告)日：2009-11-12
申请号：PCT/US2009/002844
申请日：2009-05-07
申请人： MERRION RESEARCH III LIMITED , LEE, Amanda , ADAMCZYK, Bozena , COUGHLAN, David, C. , O'TOOLE, Edel , LEONARD, Thomas, W.
发明人： LEE, Amanda , ADAMCZYK, Bozena , COUGHLAN, David, C. , O'TOOLE, Edel , LEONARD, Thomas, W.
IPC分类号： A61K38/09 , A61K47/06 , A61P5/24
CPC分类号： A61K38/09 , A61K9/2846 , A61K9/4891 , A61K47/12 , A61K47/14 , C07K7/06
摘要： The present invention provides compositions of GnRH related compounds that are suitable for oral administration, injectable administration and other forms of administration wherein the gelling characteristics of the composition are a factor. The compositions of the present invention comprise a therapeutically effective amount of one or more GnRH related compound, and a sufficient amount of at least one anti-gelling agents to reduce the gelation of the GnRH related compound. The present invention also provides processes for preparation of a composition of one or more GnRH related compound, wherein the process comprises mixing the GnRH related compound with one or more anti-gelling agents, wherein the anti-gelling agent comprises a medium chain fatty acid salt, or an ester, an ether, or a derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms or is a surface active agent.
摘要翻译：本发明提供了适合于口服给药，可注射给药和其它形式给药的GnRH相关化合物的组合物，其中组合物的胶凝特性是一个因素。本发明的组合物包含治疗有效量的一种或多种GnRH相关化合物和足够量的至少一种抗凝胶剂以减少GnRH相关化合物的凝胶化。本发明还提供一种制备一种或多种GnRH相关化合物的组合物的方法，其中该方法包括将GnRH相关化合物与一种或多种抗凝胶剂混合，其中抗凝胶剂包括中链脂肪酸盐，或中链脂肪酸的酯，醚或衍生物，并且具有约4-约20个碳原子的碳链长度，或者是表面活性剂。

18. 发明申请

WO2012094598A2 PHARMACEUTICAL COMPOSITIONS OF IRON FOR ORAL ADMINISTRATION 审中-公开
标题翻译：口服给药用铁的药物组合物
公开(公告)号：WO2012094598A2
公开(公告)日：2012-07-12
申请号：PCT/US2012/020487
申请日：2012-01-06
申请人： MERRION RESEARCH III LIMITED , CULLEN, Alan , O'TOOLE, Edel , COUGHLAN, David C. , CHALASANI, Kishore Babu , LEONARD, Thomas W.
发明人： CULLEN, Alan , O'TOOLE, Edel , COUGHLAN, David C. , CHALASANI, Kishore Babu , LEONARD, Thomas W.
IPC分类号： A61K33/26 , A61K31/192 , A61K31/19 , A61K31/07 , A61K31/355 , A61K31/375 , A61K9/20 , A61K47/48
CPC分类号： A61K47/48015 , A61K9/2013 , A61K9/2018 , A61K33/26 , A61K45/06 , A61K47/52 , A61K47/547
摘要： The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.
摘要翻译：本发明一般涉及具有中链脂肪酸盐的铁化合物的口服给药药物组合物。本发明还涉及使用该药物组合物治疗铁缺乏症和相关疾病的方法。

19. 发明申请

WO2011120033A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION 审中-公开
标题翻译：选择性因子XA抑制剂用于口服管理的药物组合物
公开(公告)号：WO2011120033A1
公开(公告)日：2011-09-29
申请号：PCT/US2011/030159
申请日：2011-03-28
申请人： MERRION RESEARCH III LIMITED , LEONARD, Thomas W. , COUGHLAN, David C. , CULLEN, Alan
发明人： LEONARD, Thomas W. , COUGHLAN, David C. , CULLEN, Alan
IPC分类号： A01N25/26 , A01N25/34 , A61K9/42
CPC分类号： A61K9/1075 , A61K9/009 , A61K31/715 , A61K31/727 , A61K47/12
摘要： The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.
摘要翻译：本发明提供用于口服给药的药物组合物，其包含治疗有效量的选择性因子Xa抑制剂或其药学上可接受的盐和增强剂，其中所述增强剂是中链脂肪酸或其盐，酯，醚或衍生物中链脂肪酸，并具有约4至约20个碳原子的碳链长度。本发明还提供一种在口服给药后在对象物中获得选择性因子Xa抑制剂的可重复生物利用度的方法，其包括口服给药如上所述的药物组合物。

20. 发明公开

EP2651395A1 PHARMACEUTICAL COMPOSITIONS OF SELECTIVE FACTOR XA INHIBITORS FOR ORAL ADMINISTRATION 审中-公开
标题翻译：药物组合物选择性Xa因子抑制剂口服
公开(公告)号：EP2651395A1
公开(公告)日：2013-10-23
申请号：EP11849444.2
申请日：2011-09-23
申请人： Merrion Research III Limited
发明人： LEONARD, Thomas W. , COUGHLAN, David C. , CULLEN, Alan
IPC分类号： A61K9/00
CPC分类号： A61K31/702 , A61K9/2833 , A61K47/12
摘要： The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式